Page 5,527«..1020..5,5265,5275,5285,529..5,5405,550..»

Future medicine: Stem cells can leverage silica nanoparticles to track where they actually go

Posted: Published on March 26th, 2013

Giving patients stem cells packaged with silica nanoparticles could help doctors determine the effectiveness of the treatments by revealing where the cells go after theyve left the injection needle. Researchers from Stanford University report in a paper published on Wednesday in the journal Science Translational Medicine that silica nanoparticles taken up by stem cells make the cells visible on ultrasound imaging. While other imaging techniques such as MRI can show where stem cells are located in the body, that method is not as fast, affordable, or widely available as an ultrasound scanner, and more importantly, it does not offer a real-time view of injection, say experts. Stem cells have significant medical promise because they can be turned into other types of living cell. As well as helping doctors adjust therapeutic dosages in patients, the new technique could help scientists perfect stem cell treatments, says senior author Sanjiv Gambhir. For the most part, researchers shoot blindlythey dont quite know where the cells are going when they are injected, they dont know if they home in to the right target tissue, they dont know if they survive, and they dont know if they leak into other tissue types, says Gambhir. This, in … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Future medicine: Stem cells can leverage silica nanoparticles to track where they actually go

Why This Stock Is Poised for Long-Term Success

Posted: Published on March 26th, 2013

By Terry Chrisomalis - March 25, 2013 | Tickers: BMY, PFE, SRPT | 0 Comments Terry is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. There is currently a big medical need for a drug that treats Duchenne Muscular Dystrophy. This disease basically halts motor function and movement as the years go bye. There are hardly any options for these patients, and a breakthrough drug from a pharmaceutical company can prove to be monumental for them. One such company has achieved tremendous results in Duschenne Muscular Dystrophy, and this company is known as Sarepta Therapeutics(NASDAQ: SRPT). Results that matter On Oct. 3, 2012, Sarepta Therapeutics announced results from its phase two trial in Duschenne Muscular Dystrophy. Patients in the study, who took eteplirsen, were on average able to walk 89 meters more than those who just took the placebo drug instead after 48 weeks. What's even more incredible is that when patients had muscle biopsies performed on them at the beginning of the study, researchers noticed that they had no dystrophin proteins being created. But by the end of the study, the levels of dystrophin protein … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Why This Stock Is Poised for Long-Term Success

Autism: One in 50 children in U.S. have it, study says – Video

Posted: Published on March 26th, 2013

Autism: One in 50 children in U.S. have it, study says A new federal study suggest one in 50 children in the U.S. suffer from autism. Norah O'Donnell reports. Get more at http://www.cbsnews.com/ Click HERE to SUB... By: CBSNewsOnline … Continue reading →

Comments Off on Autism: One in 50 children in U.S. have it, study says – Video

Autism Treatment Network on KCAL News – Video

Posted: Published on March 26th, 2013

Autism Treatment Network on KCAL News By: lokepuf … Continue reading →

Comments Off on Autism Treatment Network on KCAL News – Video

Autism Speaks locally

Posted: Published on March 26th, 2013

Published: Monday, March 25, 2013, 9:00p.m. Updated 6 hours ago The letter Help autism locally (March 22 and TribLIVE.com) by Jen Forsyth, Autism Center of Pittsburgh fundraising director, maligned Autism Speaks as being too much of a national organization to be of use locally. That's not correct. Autism Speaks is the world's leading research and advocacy organization, but we also directly support local communities. We fund Pittsburgh's Autism Treatment Network (ATN), a one-stop shop providing a family-focused continuum of care, including diagnosis, evaluations, resources and therapies. From the expert specialists participating in our ATNs, we provide families free tool kits focusing on sleep disorders, challenging behaviors and gastrointestinal disorders, in addition to our many other free tool kits. We continually refer our families to local service providers' services and events and will never ask our families to choose which organization to support. Our mission is clear; we need to work together to unite the autism community as one strong voice to change the future for all who struggle with autism. The work Autism Speaks does is more important than ever in light of the new Centers for Disease Control and Prevention prevalence survey result of one in 50 school-age children … Continue reading →

Comments Off on Autism Speaks locally

Autism Matters – to Everyone: Canadian Institutes of Health Research Experts Discuss the Autism Spectrum

Posted: Published on March 26th, 2013

Autism matters to everyone Canadian Institutes of Health Research experts discuss the autism spectrum ATTENTION: Assignment editors, health, research and science reporters Ottawa, ON (March 25, 2013) People on the autism spectrum stand out: they are different in how they act, how they move, and how they respond to others. Whether they are your child, your colleague or your student, from infants to adults, they may have both extreme difficulties and extraordinary achievements. In many ways, researchers are working hard to improve the lives of people on the autism spectrum across the lifespan. In light of World Autism Awareness Day (April 2), CIHR-funded researchers are available to discuss autism and how it matters to everyone. Experts: Who is responsible for my sons behaviour? Uncovering the genetic causes of autism Dr. Steve Scherer, CIHR-funded researcher (Toronto, Ontario) No look, no smile? Detecting autism at an early age for better outcomes Dr. Lonnie Zwaigenbaum, CIHR-funded researcher (Edmonton, Alberta) Dr. Jessica Brian, CIHR-funded researcher (Toronto, Ontario) Autism spectrum disorder and mental health problems Helping children who live with autism deal with emotional challenges Dr. Jonathan Weiss, CIHR Chair in Autism Treatment and Care Research (Toronto, Ontario) Changing perceptions The advantages of people with … Continue reading →

Comments Off on Autism Matters – to Everyone: Canadian Institutes of Health Research Experts Discuss the Autism Spectrum

Expert Alert – Autism matters – to everyone

Posted: Published on March 26th, 2013

Canadian Institutes of Health Research experts discuss the autism spectrum OTTAWA, March 25, 2013 /CNW/ - People on the autism spectrum stand out: they are different in how they act, how they move, and how they respond to others. Whether they are your child, your colleague or your student, from infants to adults, they may have both extreme difficulties and extraordinary achievements. In many ways, researchers are working hard to improve the lives of people on the autism spectrum across the lifespan. In light of World Autism Awareness Day (April 2), CIHR-funded researchers are available to discuss autism and how it matters to everyone. Experts: Who is responsible for my son's behaviour? Uncovering the genetic causes of autism Dr. Steve Scherer, CIHR-funded researcher (Toronto, Ontario) No look, no smile? Detecting autism at an early age for better outcomes Dr. Lonnie Zwaigenbaum, CIHR-funded researcher (Edmonton, Alberta) Dr. Jessica Brian, CIHR-funded researcher (Toronto, Ontario) Autism spectrum disorder and mental health problems - Helping children who live with autism deal with emotional challenges Dr. Jonathan Weiss, CIHR Chair in Autism Treatment and Care Research (Toronto, Ontario) Changing perceptions - The advantages of people with autism and their integration in the society Dr. Laurent … Continue reading →

Comments Off on Expert Alert – Autism matters – to everyone

International Autism Conference Presents Cutting-Edge Research and Treatment Approaches

Posted: Published on March 26th, 2013

NEW YORK, NY--(Marketwire - Mar 25, 2013) - A recent study from the Centers for Disease Control and Prevention states that 1 in 50 school-age children are diagnosed with autism. Roughly 1 million children ages 6 to 17 face formidable challenges in communication, behavior, and social interaction. On June 5th, 2013, ICare4Autism, the International Center for Autism Research & Education, is gathering leading clinicians and researchers at the Albert Einstein College of Medicine in conjunction with Montefiore Medical Center, who will participate in a conference in 2 tracks: Bio-Medical and Education-Behavioral Research and Practice.The conference has one critically important mission: to present cutting-edge research on autism and catalyze groundbreaking treatment approaches. The annual, cross-disciplinary conference defines the conversation on promising treatment and educational initiatives, synthesizing cutting-edge research from leading institutions, laying the groundwork for effective educational approaches in schools, and presenting the most recent findings from the world's top practitioners, as autism prevalence increases. List of speakers: Joshua Weinstein, Ph.D., MBAFounder & CEO of ICare4Autism, USA and Israel ICare4Autism Global Autism Initiatives Eric Hollander, M.D.Director of the Autism Spectrum Program at Albert Einstein College of Medicine/Montefiore Medical Center and Chairman of the ICare4Autism Advisory Council Inflammation, Temperatureand Personalized Therapeutics of … Continue reading →

Comments Off on International Autism Conference Presents Cutting-Edge Research and Treatment Approaches

Research and Markets Announces The Release of ‘Neuromodulation Market – Forecasts to 2017’

Posted: Published on March 26th, 2013

DUBLIN, March 25, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/t8zp6f/neuromodulation) has announced the addition of the "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Research and Markets Announces The Release of ‘Neuromodulation Market – Forecasts to 2017’

Neuralstem Secures $8 Million In Debt Financing From Hercules

Posted: Published on March 26th, 2013

ROCKVILLE, Md., March 25, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced today that it secured $8 million in debt financing with Hercules Technology Growth Capital (HTGC), to fund the company's capital budget through late 2014. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) "This debt financing extends our cash runway well into late 2014 at a critical time in our clinical product development cycle. We have multiple NSI-566 cell therapy clinical trials planned this year, building on our successful ALS Phase I trial, including the upcoming phase II ALS in the U.S.; both chronic and acute spinal cord injury in the U.S. and South Korea, respectively; ALS in Mexico, and stroke in China, in addition to completing the NSI-189/Phase Ib trial in major depressive disorder," said Neuralstem's President and CEO Richard Garr. "We are pleased to have the support of leading life sciences and technology investor, Hercules." "Neuralstem's unique stem cell platform has the potential to address a serious unmet medical need in the ALS and spinal cord injury patient populations, as well as other indications. The team's progress to date is the result of years of meticulous research and development. We are proud to be a strong financial partner," said Chad Norman, managing director … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Neuralstem Secures $8 Million In Debt Financing From Hercules

Page 5,527«..1020..5,5265,5275,5285,529..5,5405,550..»